Advertisement

Internal and Emergency Medicine

, Volume 13, Issue 7, pp 993–995 | Cite as

Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients?

  • Franco Piovella
  • Diana Irina Iosub
IM - COMMENTARY

In recent years, the burden of VTE in hospitalized medical patients has shifted to the post-hospital discharge period. The shortened hospital length of stay (LOS) has dampened treatment effects of in-hospital thromboprophylaxis. Recent studies report that the risk of symptomatic VTE persist after discharge [1, 2]. With shorter hospitalization (4–5 days), in-hospital prophylaxis may not be enough, and an extended prophylaxis may be necessary. It has been demonstrated that VTE risk can extend up to 90 days (peak 35–45 days) after index hospitalization [3].

Moreover, with the aging of the population with multiple comorbidities, some patients do not make it to the hospital unless they are really sick, and are more likely to be managed as outpatients. We therefore have to identify who should receive extended prophylaxis at home. Patient-related morbidities increase VTE risk [1, 4], and intrinsic patient risk factors have an additive, if not a multiplicative impact on the risk of the VTE.

Bas...

Notes

Compliance with ethical standards

Conflict of interest

Authors declare that they have no conflict of interest.

Statement of human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

None.

References

  1. 1.
    Hull RD, Merali T, Mills A et al (2013) Venous thromboembolism in elderly high-risk medical patients: time course of events and influence of risk factors. Clin Appl Thromb Haemost 19:357–362CrossRefGoogle Scholar
  2. 2.
    Mahan CE, Fisher MD, Mills RM et al (2013) Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patients population. Thromb Res 132:520–526CrossRefGoogle Scholar
  3. 3.
    Spencer FA, Lessard D, Emery C et al (2007) Venous thromboembolism in the outpatient setting. Arch Intern Med 167:1471–1475CrossRefGoogle Scholar
  4. 4.
    Kahn SR, Lim W, Dunn AS et al (2012) Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e195S–e226SCrossRefGoogle Scholar
  5. 5.
    Hull RD, Schellong SM, Tapson VF et al (2010) Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med 153:8–18CrossRefGoogle Scholar
  6. 6.
    Cohen AT, Spiro TE, Buller HR et al (2013) Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med 368:513–523CrossRefGoogle Scholar
  7. 7.
    Goldhaber SZ, Leizorovicz A, Kakkar AK et al (2011) Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med 365:2167–2217CrossRefGoogle Scholar
  8. 8.
    Cimminiello C, Prandoni P, Agnelli G et al (2017) Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis. Intern Emerg Med 12:1291–1305CrossRefGoogle Scholar
  9. 9.
    Barbar S, Noventa F, Rossetto V et al (2010) A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 8:2450–2457CrossRefGoogle Scholar
  10. 10.
    Spyropoulos AC, Anderson FA Jr, FitzGerald G, IMPROVE Investigators et al (2011) Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 140:706–714CrossRefGoogle Scholar
  11. 11.
    Cohen AT, Harrington RA, Goldhaber SZ et al (2016) Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 375:534–544CrossRefGoogle Scholar
  12. 12.
    Ageno W (2017) Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? Yes. Intern Emerg Med.  https://doi.org/10.1007/s11739-017-1723-8 CrossRefPubMedGoogle Scholar
  13. 13.
    Marongiu F, Barcellona D (2018) Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? No. Intern Emerg Med.  https://doi.org/10.1007/s11739-018-1843-9 CrossRefPubMedGoogle Scholar
  14. 14.
    Cohen AT, Spiro TE, Spyropoulos AC et al (2014) D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost 12:479–487CrossRefGoogle Scholar
  15. 15.
    Raskob GE, Spyropoulos AC, Zrubek J et al (2016) The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost 115:1240–1248CrossRefGoogle Scholar
  16. 16.
    Cohen AT, Harrington R, Goldhaber SZ et al (2015) Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. Am Heart J 169:186–187CrossRefGoogle Scholar
  17. 17.
    Gibson CM, Chi G, Halaby R et al (2017) Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients. Circulation 135:648–665CrossRefGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna 2018

Authors and Affiliations

  1. 1.Thrombosis UnitIRCCS Istituti Clinici Scientifici MaugeriPaviaItaly
  2. 2.Thrombosis UnitOspedale A. ManzoniLeccoItaly

Personalised recommendations